Initial experience with thulium fiber laser for prostate enucleation: Analysis of the intraoperative and short-term outcomes in a prospective, multicenter cohort.

INTRODUCTION: Holmium laser enucleation of the prostate has rapidly become the gold standard for the surgical treatment of benign prostate hyperplasia, although thulium fiber laser (TFL) has also been postulated as an effective and safe alternative for prostate enucleation. The aim of this study is to describe our initial experience with the TFL for endoscopic enucleation of the prostate. MATERIAL AND METHODS: All patients proposed to TFL prostate enucleation were included in the analysis, regardless their prostate volume, catheter status and severity of symptoms, in 3 centers. Preoperative characteristics, intraoperative times and functional 3-months follow-up variables were collected, along with complications. RESULTS: Fifty-six patients were available, with a mean age of 68.7 years. Enucleation and morcellation efficiencies were 2.04 and 7.47 g/min, respectively. Median hospital stay was one day. Comparable functional data, pre and 3-month post-surgery was: mean prostate volume 88.9 vs 21.3 g, maximum urinary flow 13.2 vs 27.3 ml/s, post-void residual volume 149 vs 7.8 ml, prostatic specific antigen level 11.2 vs 1 ng/ml, and International Prostate Symptom Score 20.75 vs 3.96. Fourteen out of 56 (25%) patients presented with complications grade ≤2, according to the Clavien-Dindo classification. DISCUSSION: With wider evidence for other urological indications, very recent evidence about the suitability of TFL for prostate enucleation has arisen, since the first case described in 2021. Our results seem to back up these previous successful experiences as long as we obtained good intraoperative and short term follow-up functional results. However, there is still a need of longer follow-up data. CONCLUSIONS: TFL represents a novel technology for prostate enucleation, with a good intraoperative and short follow-up functional results, and a safety profile similar to the observed for those techniques that have been wider used for this indication. Further studies with longer follow-up periods and comparative with these other techniques are necessary.

Linfadenectomía de rescate en pacientes con cáncer de próstata tratados con prostatectomía radical o radioterapia y tomografía por emisión de positrones (PET) con colina positiva / Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan

Introducción y objetivos: La recidiva ganglionar en el cáncer de próstata es un escenario terapéutico controvertido. Las guías clínicas recomiendan el uso de terapia hormonal, tratamiento "la carta" o incluir en ensayos clínicos. Estudiamos en el presente estudio el impacto de la linfadenectomía de rescate en pacientes seleccionados. Material y métodos: Revisamos retrospectivamente a 23 pacientes consecutivos con cáncer de próstata tratados mediante prostatectomía radical o radioterapia externa, a quienes se les practicó linfadenectomía de rescate desde diciembre del 2005 hasta noviembre del 2015. Se realizó análisis univariante y bivariante para evaluar la relación entre factores de riesgo y respuesta a la linfadenectomía. Resultados: Encontramos que en los pacientes con respuesta bioquímica; la hormonoterapia fue retrasada 14,9 meses comparándolo con los que no respondieron (2,8 meses), p = 0,00026. A pesar de que no se alcanzó la significación estadística (p = 0,072), el tiempo de duplicación de PSA podría ser un factor pronóstico de recidiva radiológica ya que los pacientes con tiempo de duplicación < 6 meses desarrollaron recidiva radiológica 7,6 meses antes. Conclusiones: La linfadenectomía de rescate es un tratamiento que puede retrasar el uso de hormonoterapia en pacientes seleccionados

Introduction and objectives: Nodal prostate cancer recurrence is a challenging scenario. Current guidelines recommend the use of androgen deprivation therapy, tailored treatment or clinical trials. We studied the impact of Salvage lymph node dissection in selected patients. Material and methods: We retrospectively reviewed records of 23 consecutive patients with prostate cancer and previous Radical prostatectomy or Radiotherapy who underwent SLND from December 2005 to November 2015. Results: We found that in patients that showed biochemical response the introduction of ADT was delayed 14.9 months compared to patients that did not responded (2.8 months) p = 0.00026. Furthermore although statistical significance was not reached (p = 0.072) PSA-DT could be a potential prognostic factor of radiological recurrence since patients with PSA-DT < 6 months developed radiological recurrence 7.6 months earlier compared to their counterparts. Conclusions: Salvage lymph node dissection is a potential treatment that could delay ADT in selected patients

Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan. / Linfadenectomía de rescate en pacientes con cáncer de próstata tratados con prostatectomía radical o radioterapia y tomografía por emisión de positrones (PET) con colina positiva.

INTRODUCTION AND OBJECTIVES: Nodal prostate cancer recurrence is a challenging scenario. Current guidelines recommend the use of androgen deprivation therapy, tailored treatment or clinical trials. We studied the impact of Salvage lymph node dissection in selected patients. MATERIAL AND METHODS: We retrospectively reviewed records of 23 consecutive patients with prostate cancer and previous Radical prostatectomy or Radiotherapy who underwent SLND from December 2005 to November 2015. RESULTS: We found that in patients that showed biochemical response the introduction of ADT was delayed 14.9 months compared to patients that did not responded (2.8 months) P=.00026. Furthermore although statistical significance was not reached (P=.072) PSA-DT could be a potential prognostic factor of radiological recurrence since patients with PSA-DT<6 months developed radiological recurrence 7.6 months earlier compared to their counterparts. CONCLUSIONS: Salvage lymph node dissection is a potential treatment that could delay ADT in selected patients.

[Imaging diagnosis in Focal Therapy for prostate cancer: Multiparametric Magnetic Resonance Imaging]. / Diagnóstico por imágen en Terapia Focal para el cáncer de próstata: Resonancia Magnética multiparamétrica.

The use of prostatic multiparametric MRI (mpMRI) has increased significantly over the last years, and has emerged as a crucial test for diagnosis, staging and treatment of prostate cancer (PCa). The use of the various available sequences (T2W, T1W, diffusion, perfusion and spectroscopy), as well as the different parameters they associate, not only enables to determine the group of patients subsidiary of focal ablative therapy, but also to perform a proper determination of the áreas to treat, as well as to monitor the development of therapy and to evaluate both oncological results and possible therapeutic failures. Despite the excellent results showed in the different studies, it is necessary to reach a consensus about its use on the different features associated with focal therapy, since it is a technique that requires not only large experience in its operation but also standardization. All this make it a complex technique and not free of difficulties in its interpretation.